FDA grants full approval for AstraZeneca's Calquence

17 January 2025

The US Food and Drug Administration has granted AstraZeneca’s (LSE: AZN) Calquence (acalabrutinib) full approval as part of a combination therapy for mantle cell lymphoma (MCL).

The nod covers the first-line treatment of adults who are ineligible for autologous hematopoietic stem cell transplantation. Calquence also received full approval as a monotherapy for previously treated MCL, converting its 2017 accelerated approval into a traditional one.

The decision was supported by data from the Phase III ECHO trial, which showed a 27% lower risk of disease progression or death, and a median progression-free survival (PFS) of 66.4 months, compared to 49.6 months in the comparator group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical